Nplate (Romiplostim) Romiplate: A Genetically Recombinant Protein, Stimulates Platelet Production Via Stimulation of the Thrombopoietin Receptors - Global Drug Insight and Market Forecast 2017-2030

Dublin, Dec. 30, 2020 (GLOBE NEWSWIRE) -- The "Nplate (Romiplostim) Romiplate - Drug Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Nplate (romiplostim) Romiplate - Drug Insight and Market Forecast - 2030 report by the publisher outlays comprehensive insights of the product indicated for the treatment of its approved condition. A detailed picture of the Nplate (romiplostim)Romiplate in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2017-2030 is provided in this report along with a detailed description of the product.

The product details cover mechanism of action, dosage and administration, route of synthesis, and pharmacological studies, including product marketed details, regulatory milestones, and other development activities. Further, it also consists of market assessments inclusive of the market forecast, SWOT analysis, and detailed analyst views. It further highlights the market competitors, late-stage emerging therapies, and patent details in the global space.

Romiplate/ Nplate, a genetically recombinant protein, stimulates platelet production via stimulation of the thrombopoietin receptors. Chronic ITP is normally treated with pharmaceuticals that improve blood platelet count by suppressing platelet destruction, but Romiplate/ Nplate, serves to improve platelet counts by stimulating platelet production.

Romiplostim was first approved by the U.S. Food and Drug Administration (FDA) on August 22, 2008, then approved by European Medicine Agency (EMA) on February 4, 2009, Pharmaceuticals and Medicals Devices Agency of Japan (PMDA) on January 21, 2011. It was developed and marketed as Nplate by Amgen (also marketed as Romiplate by Kyowa Hakko Kirin). Nplate and Romiplate are available as injection (lyophilized powder) for subcutaneous use, containing 250 mcg or 500 mcg of Romiplostim in single-use vials.

The recommended initial dose is 1 mcg/kg once daily. The safety and efficacy of Nplate in adults with chronic ITP were assessed in two double-blind, placebo-controlled clinical studies and in an open-label extension study.

Scope of the report

The report provides insights into:

• A comprehensive product overview including the product description, mechanism of action, dosage and administration, route of synthesis, pharmacological studies (pharmacodynamics and pharmacokinetics) and adverse reactions.

• Elaborated details on regulatory milestones and other development activities have been provided in this report.

• The report also highlights the drug marketed details across the United States, Europe and Japan.

• The report also covers the patent's information with expiry timeline around Nplate (romiplostim)Romiplate.

• The report contains historical and forecasted sales for Nplate (romiplostim)Romiplate till 2030.

• Comprehensive coverage of the late-stage emerging therapies (Phase III) in the space with a brief snapshot of the details.

• The report also features the SWOT analysis with analyst insights and key findings of Nplate (romiplostim)Romiplate.

Nplate (romiplostim)Romiplate Clinical Assessment

The report provides the clinical trials information of Nplate (romiplostim)Romiplate covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights

• In the coming years, the market scenario for Nplate (romiplostim)Romiplate is set to change due to the extensive research in the treatment of the indicated condition and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

• The companies and academics are working to assess challenges and seek opportunities that could influence Nplate (romiplostim)Romiplate dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.

• Other approved products for the disease are giving market competition to Nplate (romiplostim)Romiplate and launch of late-stage emerging therapies in the near future will significantly impact the market.

• A detailed description of regulatory milestones, development activities, and some key findings provide the current market scenario of Nplate (romiplostim)Romiplate.

• Our in-depth analysis of the sales data of Nplate (romiplostim)Romiplate from 2017 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Nplate (romiplostim)Romiplate in the market.

Key Topics Covered:

1. Product Overview
1.1. Indication
1.2. Mechanism of Action
1.3. Dosage and Administration
1.4. Dosage Forms and Strengths
1.4.1 Route of Synthesis
1.5. Pharmacology
1.5.1 Pharmacodynamics
1.5.2 Pharmacokinetics
1.6. Adverse Reactions
1.7. Product Snapshot
1.8. Development Milestones of Nplate (romiplostim)Romiplate
1.9. Marketed Details
1.9.1 United States
1.9.2 Europe
1.9.3 Japan
1.10. Patent Details

2. SWOT Analysis
2.1. Analyst Views

3. Regulatory Milestones
3.1. Approvals
3.2. Research and Development
3.3. Clinical Trials Information
3.4. Safety and Efficacy
3.5. Product Developmental Activities

4. Market Assessment
4.1. 7MM Market Analysis
4.2. United States
4.3. Europe
4.4. Japan
4.5. Key Findings

5. Market Competitors

6. Emerging Therapies

7. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/6xyp7c

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900